A pediatric ciliopathy ecosystem
with a therapeutic pipeline addressing genetic diseases of the kidney, retina, bone and cartilage
A pediatric ciliopathy ecosystem
with a therapeutic pipeline addressing genetic diseases of the kidney, retina, bone and cartilage
Supporters
Partnerships
In 2019, Medetia was supported by the Human Health Startup Factory consortium, and it was granted DeepTech labelling.
In 2021, Medetia has been selected for inclusion in the Challenges media’s “100 start-ups to invest in in 2021” in the Medtech and Biotech category; also it was one recipient of the i-Lab innovation competition.
In 2023, MEDETIA announces its partnership with Ipsen, an international biopharmaceutical group, within the framework of the innovative research program Hybridge™, based on the prospection of medicine candidates for rare diseases.
Ciliopathies
Ciliopathies are a large family of genetic diseases whose common feature is a dysfunction of the primary cilia – affecting kidney, retina and cartilage, but not only.
Medetia is – since 2019 – has been part of the RHU (« Recherche Hospitalo-Universitaire en santé » ) consortium C’IL-LICO, as industrial partner. The C’IL-LICO project proposes a new approach for the management of a group of rare and serious genetic diseases, ciliopathies that cause the deterioration of renal function and lead to end-stage renal failure. (Image modified swissbiopics.org)
Featured news
2022.05.30
Medetia consolidates its position at Imagine Institute with a master research agreement
2022.01.20
Medetia signs master research agreement with Inserm Transfer
About Us
OUR FOUNDERS
Lead the strategic orientation and gouvernance. 20y experience in Pharma Industry.
Accelerator of partnerships, with strong pharma and biotech experience.